Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial

Stroke

Volumn 44, Issue 9, 2013, Pages 2381-2387

  Pancioli, Arthur M ^a,b   Adeoye, Opeolu ^a,b   Schmit, Pamela A ^a,b   Khoury, Jane ^d   Levine, Steven R ^e   Tomsick, Thomas A ^a,c   Sucharew, Heidi ^d   Brooks, Claudette E ^f   Crocco, Todd J ^f   Gutmann, Laurie ^f   Hemmen, Thomas M ^g   Kasner, Scott E ^h   Kleindorfer, Dawn ^a,b   Knight, William A ^a,b   Martini, Sharyl ^a,b   McKinney, James S ⁱ   Meurer, William J ^j,k   Meyer, Brett C ^g   Schneider, Alexander ^l   Scott, Phillip A ^j   Starkman, Sidney ^m   Warach, Steven ⁿ   Broderick, Joseph P ^a,b   more..

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e Downstate Health Sciences University   (United States)

^f WEST VIRGINIA UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l Mission Hospital   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

more..

Author keywords

Clinical trial; Eptifibatide; Ischemic stroke; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; EPTIFIBATIDE; PLACEBO;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE;

CLINICAL TRIAL; EPTIFIBATIDE; ISCHEMIC STROKE; TISSUE PLASMINOGEN ACTIVATOR;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84884502882     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001059     Document Type: Article

References (11)

1. Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. The N Engl J Med. 1995;333:1581-1587
2. Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
3. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008;39:3268-3276.
4. Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, et al; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
5. Shaw GJ, Meunier JM, Lindsell CJ, Pancioli AM, Holland CK. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res. 2010;126:e305-e311.
6. Berger C, Fiorelli M, Steiner T, Schäbitz WR, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330-1335.
7. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000;31:2335-2341.
8. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, et al NET-PD Investigators. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006;66:628-633.
9. Herson J, Carter SK. Calibrated phase II clinical trials in oncology. Stat Med. 1986;5:441-447.
10. Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Röther J, et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke. 2011;42:2388-2392.
11. Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a doubleblind randomized trial. Cerebrovasc Dis. 2010;29:275-281.